Randi Jenssen Hagerman, M.D., F.A.A.P. for UC Davis Health

Randi Jenssen Hagerman, M.D., F.A.A.P.

Distinguished Professor, Department of Pediatrics

Endowed Chair in Fragile X Research

Medical Director of the MIND

To see if Randi Jenssen Hagerman is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Reviews

Specialties

Pediatric Child Development & Behavior

Department

Pediatrics

Locations and Contact

2825 50th St.
Sacramento, CA 95817

Get Directions

Additional Numbers

Phone

916-703-0247

Clinic Phone

916-703-0257

Clinic Phone

916-703-0300

Clinic Fax

916-703-0240

Clinic Referral Phone

916-703-0236

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

There are many treatments that can make a difference in the lives of children and adults with fragile X associated disorders and Dr. Hagerman is on the cutting edge in finding new treatments for all of the disorders listed above. A multimodality treatment approach typically works best including behavioral/educational interventions combined with psychopharmacological interventions that can reverse the neurobiological abnormalities caused by a genetic mutation. and therefore they are targeted treatments.

Clinical Interests

Dr. Randi Hagerman is a Developmental and Behavioral Pediatrician at the MIND Institute and she specializes in neurogenetic disorders and their treatment. She sees children and adults with Fragile X syndrome, premutation disorders, autism in addition to adults with the fragile X-associated tremor ataxia syndrome (FXTAS), FXPOI meaning fragile X -associated primary ovarian failure and FXAND meaning fragile X-associated neuropsychiatric disorders. She often facilitates the patient's participation in research including new treatments for the disorders mentioned above.

Research/Academic Interests

Dr. Hagerman has carried out many studies in fragile X syndrome including autism including studies of metformin, Cannabidiol (CBD), BPN14770 (a phosphoresterase PDE4D inhibitor) that raises cAMP, trofinetide and many other targeted treatments. Further treatments in FXTAS include memantine, allopregnanolone and Anavex 2-73, a sigma 1 agonist that improves mitochondrial function. Dr. Hagerman also has a special interest in molecular biomarkers with her collaborators Dr. Paul Hagerman and Dr. Flora Tassone.

Division

Child Development and Behavior

Center/Program Affiliation

UC Davis Children's Hospital
UC Davis MIND Institute

Undergraduate School

B.S., Zoology, UC Davis, Davis CA 1971

Medical School

M.D., Stanford University School of Medicine, Stanford CA 1975

Internship

PL1-Pediatrics, Stanford Hospital, Stanford CA 1975-1976

Residency

PL2 Pediatrics, Stanford Hospital, Palo Alto CA 1976-1977

Residency

PL3, UC San Diego, San Diego CA 1978-1979

Fellowship

Neurodevelopmental Disorders, UC San Diego, San Diego CA 1979-1980

Hibbard Williams M.D., Lifetime Achievement Award, 2022

Emil M. Mrak International Award, Cal Aggie Alumni Association, 2017

International Sisley-Jerome Lejeune Award, Strasbourg, 2014

C. Anderson Aldrich Award for Outstanding Career Achievement, American Academy of Pediatrics, SODBP, 2014

Distinguished Scholarly Public Service Award, UC Davis, Office of the Academic Senate, 2014

List of Published Work on MyNCBI:

http://www.ncbi.nlm.nih.gov/sites/myncbi/randi.hagerman.1/bibliography/40454177/public/?sort=date&direction=ascending

Aishworiya R, Protic D, Hagerman R. Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications. J Neurol. 2022 Sep;269(9):4676-4683. doi:10.1007/s00415-022-11209-5. Epub 2022 Jun 20. PMID:35723724.

Protic DD, Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, Hagerman RJ, Budimirovic DB. Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. Int J Mol Sci. 2022 Feb 9;23(4):1935. doi:10.3390/ijms23041935. PMID:35216055.

Wang JY, Grigsby J, Placido D, Wei H, Tassone F, Kim K, Hessl D, Rivera SM, Hagerman RJ. Clinical and Molecular Correlates of Abnormal Changes in the Cerebellum and Globus Pallidus in Fragile X Premutation. Front Neurol. 2022 Feb 8;13:797649. doi:10.3389/fneur.2022.797649. PMID:35211082.

Salcedo-Arellano MJ, Hagerman RJ. Recent research in fragile X-associated tremor/ataxia syndrome. Curr Opin Neurobiol. 2022 Feb;72:155-159. doi:10.1016/j.conb.2021.11.006. Epub 2021 Dec 7. PMID:34890957.

Johnson D, Santos E, Kim K, Ponzini MD, McLennan YA, Schneider A, Tassone F, Hagerman RJ. Increased Pain Symptomatology Among Females vs. Males With Fragile X-Associated Tremor/Ataxia Syndrome. Front Psychiatry. 2022 Jan 20;12:762915. doi:10.3389/fpsyt.2021.762915. PMID:35126193.

Hagerman RJ, Hagerman PJ. Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:365-381. doi:10.1146/annurev-pharmtox-052120-090147. Epub 2021 Sep 9. PMID:34499526.

Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on Psychopharmacological Treatment of Autism Spectrum Disorder. Neurotherapeutics. 2022 Jan;19(1):248-262. doi:10.1007/s13311-022-01183-1. Epub 2022 Jan 14. PMID:35029811.

Sodhi DK, Hagerman R. Fragile X Premutation: Medications, Therapy and Lifestyle Advice. Pharmgenomics Pers Med. 2021 Dec 29;14:1689-1699. doi:10.2147/PGPM.S338846. PMID:35002287.

Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management. Nat Rev Neurol. 2016 Jul;12(7):403-12. doi:10.1038/nrneurol.2016.82. Epub 2016 Jun 24. PMID:27340021.